← Oncology Approval Tracker

FDA DECISION ·

Koselugo

selumetinib · AstraZeneca Pharmaceuticals

FDA approvalNew or expanded indicationNF1-associated plexiform neurofibromas
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.

LAMPGEN ANALYSIS

Why it matters

Adult evidence supported extending this MEK inhibitor to patients with symptomatic benign tumors previously covered only by the pediatric indication.

What research teams should watch

Ensure adult NF1 referral networks can support volumetric imaging and ocular and cardiac assessments.

PRIMARY RECORDS

Sources